AJMC September 27, 2024
Out-of-pocket costs for biosimilars and generics are still high for patients despite these drugs leading to estimated savings of $445 billion in 2023.
A report from the Association for Accessible Medicines (AAM) found that biosimilars and generics were able to save the US $445 billion by the end of 2023. However, despite these savings, the out-of-pocket (OOP) costs to patients remains high, which can affect the impact and adoption of biosimilars and generics across the nation.1,2
AAM released their annual savings report, which is released in an effort to educate the public on the cost of biosimilars and generics on September 6.3 The report published notable statistics about generics and biosimilars in the US, including the fact that 90% of...
Today's Sponsors
Today's Sponsor